- Study delivers data required for Phase II trial, on track to initiate next quarter - Confirms linear, dose-proportional pharmacokinetics - Complements strong safety data already reportedTORONTO--(BUSINESS WIRE)--$ATBPF--Antibe Therapeutics Inc. (TSX: A
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, infl
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International (“AGI”) announced that its Nobleford, Alberta manufacturing facility has achieved a significant safety milestone with an impressive three years of no lost time incidents. A lost time inciden
NEW YORK--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (NEO: CBST) (OTCQX: CBSTF) (FSE: 3LP) (“The Cannabist Company” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products
More than half of the U.S. population now lives in a state with adult-use cannabisCHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfo
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the thir
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology IndustrySEATTLE & CAMBRIDGE & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative the
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a third closing pursuant to its previously announced private placement of units of th
Revenue from continuing operations increased 5.9% to $152.5 million, driven by 5.5% volume growth Loss from continuing operations of $5.7 million, compared to earnings of $2.4 million in the prior year Adjusted EBITDA from continuing operations increased
$27.2 million in cash $419.2 million in sales, an 8.2 percent year-over-year increase $1,271.6 million in year to date sales, an 18.3 percent year-over-year increase Diluted earnings per share of $0.93, up 31.0 percent compared to Q3 2022 $44.0 mill
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.